
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air Inc. is experiencing a positive trajectory, highlighted by a 105% increase in fiscal 3Q26 revenue to $2.2 million, indicating strong demand for its LungFit PH device and successful penetration into the U.S. market, exemplified by its first sale to a VA Medical Center. The company's expanding international distribution network, now in 40 countries, further enhances its growth potential and market presence. Additionally, encouraging preliminary data from the intratumoral ultra-high concentration Nitric Oxide (UNO) program suggests a promising therapeutic profile, which may enhance Beyond Air's credibility and prospects as it continues to innovate in the respiratory and oncology sectors.
Bears say
Beyond Air Inc is shifting its focus for its Nitric Oxide (NO) Generator and Delivery System, now positioning it as an immunotherapy enhancer instead of merely a standalone ablation tool, which may indicate challenges in establishing a distinct market presence for the product. The change in strategy reflects possible underlying concerns regarding the effectiveness and market acceptance of their primary offering, particularly in competitive therapeutic areas like immunotherapy for respiratory diseases. These factors, combined with the company's commercialization stage and potential revenue uncertainties, contribute to a negative outlook on Beyond Air's stock.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares